



Maternal Serum Screening

Delivers Clarity and Reassurance for Healthy Outcome

Prenatal Screening Solutions

- Analysis of biochemical markers along with ultrasonographic findings is ideally performed between 11-13 weeks in 1st trimester & between 15-21 weeks in 2nd trimester.
- MedGenome utilizes Fetal Medicine Foundation (FMF - UK) approved DELFIA® technology using Life cycle software, a clinically validated platform configured as per population data.
- DELFIA is one of the only four biochemistry analyzers certified by FMF.
- As per clinical research, non-FMF certified assays lower the detection rate and increase the false positive rate leading to more invasive testing.
- Multiple of medians (MoMs) have been validated with indigenous population data.
- CAP Accredited.

Reflex NIPT

Patients in the high risk category can choose to go with Reflex NIPT test which provides a **safe, accessible, accurate, non-invasive** modality with >99% detection rate and false positive rate of 0.3%. Less than 0.5% of cases need to go for invasive testing post NIPT, as per published literature.

Pioneer in the field of NIPT (CAP accredited) since 2017

Note: NIPT is done only if the marker test is High Risk

Free Pre & Post test Genetic counseling sessions with our experts



